Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Summit plc
Summit plc
Activities:
Manufacturing
Ingredients
Research & Development
Infection Control
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Summit appoints Dr David Roblin as Chief Medical Officer
Roblin has been involved in the successful development of a number of important medicines in a range of therapy areas
Research & Development
Wellcome Trust awards Summit £4m to further develop C. Difficile antibiotic
Phase I trial to start by end of the year with results expected in first half of 2013
Research & Development
Summit agrees technology licence with Bristol-Myers Squibb
Summit will receive $100,000 fee for access to its Seglin technology
Manufacturing
Cambridge Major Labs supports Summit antibiotic project
The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Subscribe now